CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). They have strived to establish a new business model in regards to pharmaceutical development with an approach of investing in drug at early stage of its development or in the repositioning of existing drugs. CleveXel’s strategy directs its focus to disorders of the central nervous system, particularly complications arising from movement disorders and Parkinson’s disease. They are fast establishing themselves as a reputable source within the world of pharmaceutical development.
Contact
CLEVEXEL Pharma S.A.S
19, avenue du Professeur Cadiot
communication@clevexel.com
Contact : +33 1 79 84 19 35
info@clevexel.com
Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them…
Bernard Fraisse of Fareva, France’s leading CMO, discusses growth, international expansion, loyalty to France, dedication to clients, and commitment to providing high quality products. Many have predicted that pharma manufacturing…
Marc Alexander Burmeister of B. Braun France speaks about the country’s role as a production hub for B. Braun’s global operations, its 2020 strategy to reach USD 200 million in…
Jean-Paul Berthomé, the CEO of Laboratoires Expanscience, talks about the company’s global ambitions, flagship products and strategies to tackle challenges in emerging economies. With a presence in highly saturated markets,…
Shire France’s General Manager, Andrew Obenshain, speaks optimistically about the leading market conditions in France, the corporate culture of a multinational company in a niche market, and building a rapport…
As CEO of the newly formed government agency Business France, Muriel Pénicaud is passionate about championing French innovation and creativity, particularly in life sciences. She tells us about her organization’s…
The dynamic Director of ESCP Europe’s Master in Biopharmaceutical Management talks about being the reference higher education institution for programs catering to the biopharma sector, plans for more international visibility,…
Thierry Guillot, president of Chugai Pharma France, talks about the challenge of transitioning from a small organization, which revolved around one main product into a larger entity capable of delivering…
CreaPharm Group’s CEO, Eric Placet, discusses the creation of his company, ambitions for growth, and the lessons learned throughout his leadership. He also emphasizes the relevance of the size of…
LEO Pharma is expanding its global presence and continuing its leading role in the number of skin disease patients treated and in thrombosis care. Head of the company’s French affiliate,…
With over 15 years of expertise in external sterilization services for medical devices and surgical instruments, Sterience has successfully positioned itself as the market leader in France. Directing the company…
Boston Scientific is raising the bar for medical devices and services in the field of cardiology and other pathologies, including Rhythm Management, Endoscopy, Urology Pelvic Health, and Neurostimulation. European President…
Vygon CEO, Stephane Regnault, shares the international strategy of one of the largest independent French medical device companies and their continuing commitment to quality. You are one of the few mid-sized…
See our Cookie Privacy Policy Here
